ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2025
Epidemiology, prognosis, and treatment of head and neck mucoepidermoid carcinoma: a SEER-based analysis of 6228 patients (2004-2020).
Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeTo conduct a comprehensive analysis of the epidemiology, prognosis, and treatment of the head and neck mucoepidermoid carcinoma (HNMEC).
methodsPatients diagnosed with HNMEC from 2004 to 2020 were retrieved from the Surveillance, Epidemiology, and End Results database. The demographic, clinicopathological and treatment-related characteristics of the cohort were described. Associations between categorical variables were examined by Pearson's χ
resultsA total of 6228 patients were included. The 5-year OS and DSS rates were 81.1% and 89.4%, respectively. Major salivary gland MEC accounted for the largest proportion, followed by oral cavity MEC. Oral cavity MEC exhibited the most favorable survival outcome, which may be due to the higher proportion of early-stage and low-grade disease. Patients with a history of cancer before or after diagnosis of HNMEC had worse OS, but not DSS. The patterns of local treatment for HNMEC remained unchanged from 2004 to 2020. Radiotherapy (alone or combined with surgery) was associated with a worse DSS, even after adjustment. Compared to patients diagnosed between 2004 and 2009, patients diagnosed between 2010 and 2015 had statistically significant improvements in both 5-year OS (3.7%) and 5-year DSS (3.4%).
conclusionA simplified 2-tierd grading system was appropriate for HNMEC, with Grade 1/2 being low-grade, and Grade 3/4 being high-grade. Tumor stage and grade are significant prognostic factors for HNMEC. Early-stage and low-grade HNMEC could be regarded as low-risk malignancy with favorable prognosis, which could usually be effectively treated with surgery alone.
Indexed as
Identifiers
40987856What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.